ECSP10010209A - Agonistas novedosos de los receptores de glucocorticoides - Google Patents

Agonistas novedosos de los receptores de glucocorticoides

Info

Publication number
ECSP10010209A
ECSP10010209A EC2010010209A ECSP10010209A ECSP10010209A EC SP10010209 A ECSP10010209 A EC SP10010209A EC 2010010209 A EC2010010209 A EC 2010010209A EC SP10010209 A ECSP10010209 A EC SP10010209A EC SP10010209 A ECSP10010209 A EC SP10010209A
Authority
EC
Ecuador
Prior art keywords
glucocorticoid receptors
new agonists
relates
present
agonists
Prior art date
Application number
EC2010010209A
Other languages
English (en)
Inventor
David Anthony Price
Paul Alan Glossop
David Simon Millan
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010209(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of ECSP10010209A publication Critical patent/ECSP10010209A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a agonistas novedosos del receptor de glucocorticoides de la fórmula (I): y a procedimientos e intermedios para su preparación. La presente invención también se refiere a composiciones farmacéuticas que contienen estos compuestos, a su combinación con otro u otros agentes terapéuticos, así como a su uso para el tratamiento de un número de enfermedades, trastornos y afecciones inflamatorios y alérgicos.
EC2010010209A 2007-11-30 2010-05-28 Agonistas novedosos de los receptores de glucocorticoides ECSP10010209A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99135407P 2007-11-30 2007-11-30
US5724108P 2008-05-30 2008-05-30
US7955508P 2008-07-10 2008-07-10

Publications (1)

Publication Number Publication Date
ECSP10010209A true ECSP10010209A (es) 2010-06-29

Family

ID=40427125

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010209A ECSP10010209A (es) 2007-11-30 2010-05-28 Agonistas novedosos de los receptores de glucocorticoides

Country Status (32)

Country Link
US (2) US8822439B2 (es)
EP (1) EP2225256B1 (es)
JP (1) JP4686650B2 (es)
KR (1) KR101295998B1 (es)
CN (1) CN101878221B (es)
AP (1) AP2010005267A0 (es)
AR (1) AR069490A1 (es)
AU (1) AU2008331187B2 (es)
BR (1) BRPI0820447A2 (es)
CA (1) CA2706180C (es)
CL (1) CL2008003549A1 (es)
CO (1) CO6280401A2 (es)
CR (1) CR11393A (es)
DK (1) DK2225256T3 (es)
DO (1) DOP2010000161A (es)
EA (1) EA201070535A1 (es)
EC (1) ECSP10010209A (es)
ES (1) ES2399945T3 (es)
GT (1) GT201000153A (es)
IL (1) IL205356A0 (es)
MA (1) MA31867B1 (es)
MX (1) MX2010005861A (es)
NI (1) NI201000090A (es)
NZ (1) NZ585434A (es)
PA (1) PA8805801A1 (es)
PE (1) PE20091072A1 (es)
SV (1) SV2010003580A (es)
TN (1) TN2010000230A1 (es)
TW (1) TW200930378A (es)
UY (1) UY31496A1 (es)
WO (1) WO2009069032A2 (es)
ZA (1) ZA201003439B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2786086A1 (en) * 2010-01-15 2011-07-21 Rigel Pharmaceuticals, Inc. Screening assay employing dex and gdf8
TW201139369A (en) 2010-02-05 2011-11-16 Chiesi Farma Spa Pyrrolidine derivatives
CN103391945B (zh) * 2011-03-15 2016-11-09 奇斯药制品公司 异噁唑烷衍生物
CN103380142A (zh) * 2011-03-15 2013-10-30 奇斯药制品公司 异噁唑烷衍生物
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
AU2014228990B2 (en) 2013-03-15 2017-02-02 Aprecia Pharmaceuticals LLC Rapid disperse dosage form containing levetiracetam
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
WO2016133967A2 (en) * 2015-02-18 2016-08-25 Parion Sciences, Inc. Sodium channel blockers for skin disorders
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
SG10202001787QA (en) * 2016-06-02 2020-04-29 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
JP2021501130A (ja) 2017-10-05 2021-01-14 フルクラム セラピューティクス，インコーポレイテッド ＤＵＸ４の発現を低減するためのｐ３８阻害剤の使用
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3082356A1 (en) * 2017-12-01 2019-06-06 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
JP2021504430A (ja) * 2017-12-01 2021-02-15 アッヴィ・インコーポレイテッド 抗ｃｄ４０抗体薬物コンジュゲート
EP3768324B1 (en) 2018-03-22 2025-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
CN109734763A (zh) * 2019-01-20 2019-05-10 湖南科瑞生物制药股份有限公司 一种16a-羟基醋酸泼尼松龙产品的制备方法
CN109651474A (zh) * 2019-01-20 2019-04-19 湖南科瑞生物制药股份有限公司 一种16a-羟基泼尼松龙的新的制备方法
CN109575095A (zh) * 2019-01-20 2019-04-05 湖南科瑞生物制药股份有限公司 一种16a-羟基醋酸泼尼松龙的制备方法
CN109575097A (zh) * 2019-01-20 2019-04-05 湖南科瑞生物制药股份有限公司 一种16a-羟基泼尼松龙产品的新的制备方法
TWI899455B (zh) 2021-03-23 2025-10-01 美商美國禮來大藥廠 糖皮質素受體激動劑
CN117043172A (zh) * 2021-03-23 2023-11-10 伊莱利利公司 糖皮质激素受体激动剂
AR125084A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas del receptor de glucocorticoides novedosos
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
CN117580849A (zh) * 2021-06-24 2024-02-20 江苏先声药业有限公司 甾体类化合物、其药物组合物及其应用
CN120463762A (zh) * 2021-08-26 2025-08-12 映恩生物科技(上海)有限公司 一种甾体化合物及其缀合物
WO2023245106A1 (en) 2022-06-16 2023-12-21 Abbvie Biotherapeutics Inc. Anti-cd19 antibody drug conjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US8232304B2 (en) 2002-10-24 2012-07-31 G & R Pharmaceuticals, Llc Antifungal formulations
WO2005044759A2 (en) * 2003-08-14 2005-05-19 Sun Pharmaceutical Industries Limited Acetalization process for preparation of steroid compounds
WO2005028495A1 (en) * 2003-09-24 2005-03-31 Glaxo Group Limited Anti-inflammatory glucocorticoids
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
US20050227927A1 (en) 2004-03-31 2005-10-13 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis

Also Published As

Publication number Publication date
US20090227548A1 (en) 2009-09-10
CN101878221A (zh) 2010-11-03
GT201000153A (es) 2012-04-27
EP2225256B1 (en) 2013-01-09
US8822439B2 (en) 2014-09-02
KR20100074306A (ko) 2010-07-01
WO2009069032A3 (en) 2009-08-06
HK1144821A1 (en) 2011-03-11
JP2011505350A (ja) 2011-02-24
PA8805801A1 (es) 2009-07-23
AU2008331187A1 (en) 2009-06-04
ES2399945T3 (es) 2013-04-04
ZA201003439B (en) 2011-02-23
MA31867B1 (fr) 2010-11-01
TW200930378A (en) 2009-07-16
DK2225256T3 (da) 2013-03-11
NZ585434A (en) 2012-06-29
EA201070535A1 (ru) 2010-12-30
KR101295998B1 (ko) 2013-08-13
AR069490A1 (es) 2010-01-27
NI201000090A (es) 2010-10-04
CR11393A (es) 2010-05-19
MX2010005861A (es) 2010-06-11
CA2706180A1 (en) 2009-06-04
CN101878221B (zh) 2014-04-02
SV2010003580A (es) 2011-03-23
UY31496A1 (es) 2009-07-17
AP2010005267A0 (en) 2010-06-30
CL2008003549A1 (es) 2009-11-20
CO6280401A2 (es) 2011-05-20
DOP2010000161A (es) 2010-07-15
BRPI0820447A2 (pt) 2015-05-26
JP4686650B2 (ja) 2011-05-25
CA2706180C (en) 2012-10-23
TN2010000230A1 (fr) 2011-11-11
WO2009069032A2 (en) 2009-06-04
US20140336160A1 (en) 2014-11-13
EP2225256A2 (en) 2010-09-08
PE20091072A1 (es) 2009-07-23
IL205356A0 (en) 2010-12-30
AU2008331187B2 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
ECSP10010209A (es) Agonistas novedosos de los receptores de glucocorticoides
UY32675A (es) Nuevos agonistas del receptor de glucocorticoides
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
ECSP088620A (es) 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
DOP2009000148A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
CR11627A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores c-met
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
ECSP088807A (es) Tetrahidro-pirimidoazepinas como moduladores del potencial transitorio de receptor vaillinoide 1 (trpv1)
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CR20190379A (es) Moduladores del receptor de estrógeno
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
NI201100015A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico.
CO2021001174A2 (es) Inhibidores de ckd8/19
CR9595A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
UY28911A1 (es) Profármacos de esteroides con acción androgénica
CU20100110A7 (es) Agonistas novedosos de los receptores de glucocorticoides
ECSP067096A (es) Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6
UA95861C2 (en) Glucocorticoid receptor agonists
UY32718A (es) Compuestos derivados de 1, 3, 4-tiadiazol, útiles como agonistas del receptor de esfingosina 1-fosfato
ECSP099805A (es) Nuevos derivados de ácido dicarboxílico como agonistas de los receptores de s1p1
GT200500056A (es) Compuestos utiles para el tratamiento de enfermedades
CU23661B7 (es) Derivados de formamida para el tratamiento de enfermedades
CU20080116A7 (es) 3-aminociclopentanocarboxamidas como muduladores de receptores de quimioquinas